Dermatitis.
Conditions
Interventions
Intervention 1: Intervention group: Patients in drug group receive a tablet containing 10 mg of melatonin from Jalinous pharmaceutical company, every night 1 hour before bed for 4 weeks. Patients als
Sponsors
Alborz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: 12 year-old or older patients with dermatitis which has affected at least 5% of whole body Signing the consent form by the patient.
Exclusion criteria
Exclusion criteria: Patients receiving systemic treatment for their dermatitis (exception: antihistamines). Patients receiving sedatives. Patients with history of allergic reactions to Melatonin or other ingredients in tablets. If a patient refuses to continue the study at any time after the study started.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of dermatitis. Timepoint: Beginning and the end of the study. Method of measurement: SCORAD index. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Sleep. Timepoint: Beginning and the end of the study. Method of measurement: ISI and ADSS index.;Quality of Life. Timepoint: Beginning and the end of the study. Method of measurement: DLQI index.;Severity of pain. Timepoint: Beginning and the end of the study. Method of measurement: NRS index.;Severity of itching. Timepoint: Beginning and the end of the study. Method of measurement: 12-PSS index. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Daei
Alborz University of Medical Sciences
Outcome results
None listed